Vulva Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: VLV032 MIFTS: 51	Vulva Cancer Categories: Cancer diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Vulva Cancer

MalaCards integrated aliases for Vulva Cancer:

Name: Vulva Cancer ¹² ¹⁵

Carcinoma of Vulva ¹² ⁶⁰ ⁷⁴

Vulvar Carcinoma ¹² ⁶⁰ ¹⁷

Vulva Carcinoma ¹² ⁵⁶ ¹⁵

Vulvar Cancer ⁵⁴ ³⁸ ⁴⁴

Malignant Neoplasm of Vulva ¹² ⁷⁴

Vulvar Neoplasms ⁴⁵ ⁷⁴

Malignant Tumor of Vulva ¹²

Malignant Vulvar Tumor ¹²

Neoplasm of Vulva ¹²

Vulval Neoplasm ¹²

Vulvar Neoplasm ¹²

Vulval Cancer ¹²

Vulvar Tumor ¹²

Ca Vulva ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of vulva

Malignant neoplasm: Vulva, unspecified

Orphanet: ⁶⁰

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹² DOID:1245 DOID:1294

KEGG ³⁸ H00029

ICD9CM ³⁶ 184.4

MeSH ⁴⁵ D014846

NCIt ⁵¹ C3443 C4866 C7502

SNOMED-CT ⁶⁹ 94143002

ICD10 ³⁴ C51 C51.9

Orphanet ⁶⁰ ORPHA494418

EFO ¹⁷ EFO_0002921

UMLS ⁷⁴ C0042995 C0375071 C0677055

Sources

Summaries for Vulva Cancer

MedlinePlus : ⁴⁴ Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually grows slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. Often, vulvar cancer doesn't cause symptoms at first. However, see your doctor for testing if you notice A lump in the vulva Vulvar itching or tenderness Bleeding that is not your period Changes in the vulvar skin, such as color changes or growths that look like a wart or ulcer You are at greater risk if you've had a human papillomavirus (HPV) infection or have a history of genital warts. Your health care provider diagnoses vulvar cancer with a physical exam and a biopsy. Treatment varies, depending on your overall health and how advanced the cancer is. It might include surgery, radiation therapy, chemotherapy, or biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Vulva Cancer, also known as carcinoma of vulva, is related to vulva adenocarcinoma and verrucous carcinoma, and has symptoms including pelvic pain and pruritus vulvae. An important gene associated with Vulva Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are L1CAM interactions and Glioblastoma Multiforme. The drugs Gardasil and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include lymph node, testes and skin, and related phenotypes are pigmentation and respiratory system

Disease Ontology : ¹² A vulva cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

NIH Rare Diseases : ⁵⁴ Vulvar cancer is the abnormal growth of cells of the vulva, which is part of the female reproductive system and includes the vaginal lips, clitoris, and part of the vagina. Symptoms of vulvar cancer may consist of a lump (mass), itching, or unusual bleeding. Though the exact cause of this cancer is unknown, older women and those who have human papillomavirus have a higher chance of developing vulvar cancer. Treatment may include laser therapy, surgery, chemotherapy, or radiation therapy.

Wikipedia : ⁷⁷ Vulvar cancer is a malignant, invasive growth in the vulva, or the outer portion of the female genitals.... more...

Sources

Related Diseases for Vulva Cancer

Diseases related to Vulva Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)

#	Related Disease	Score	Top Affiliating Genes
1	vulva adenocarcinoma	31.5	CDKN2A KRT7 LINC01191 UPK3A
2	verrucous carcinoma	30.4	CDKN2A TP53
3	vulvar intraepithelial neoplasia	30.3	KRT7 TP53
4	anogenital venereal wart	30.2	CDKN2A TP53
5	suppressor of tumorigenicity 3	30.2	CDKN2A TP53
6	vulvar dystrophy	30.1	CDKN2A LINC01191
7	in situ carcinoma	30.1	CDKN2A EGFR TP53
8	papilloma	30.0	CDKN2A KRT13 KRT7 TP53
9	vulvar disease	29.8	CDKN2A KRT13 KRT7 LINC01191 PLXDC2 SCN10A
10	small cell carcinoma	29.8	CDKN2A EGFR KRT7 TP53
11	squamous cell carcinoma	29.8	CDKN2A EGFR SERPINB3 TP53
12	endometrial cancer	29.4	CDKN2A EGFR KRT7 TP53
13	vulva squamous cell carcinoma	29.0	CDKN2A PLXDC2 SERPINB3 SH3GL2 TP53
14	vulva verrucous carcinoma	11.5
15	vulvar basal cell carcinoma	11.2
16	vaginal disease	11.1
17	bartholin's gland carcinoma	11.1
18	vulva basal cell carcinoma	11.1
19	vulvar sebaceous carcinoma	11.1
20	vulvar eccrine porocarcinoma	11.1
21	vulvar clear cell hidradenocarcinoma	11.1
22	vulvar glandular tumor	11.1
23	vulvar melanoma	11.1
24	vulvar sarcoma	11.1
25	clitoris cancer	11.1
26	brain ependymoma	10.4	EGFR TP53
27	malignant peritoneal mesothelioma	10.4	CDKN2A EGFR
28	peritoneal mesothelioma	10.4	CDKN2A EGFR
29	anaplastic oligodendroglioma	10.4	CDKN2A EGFR
30	recurrent respiratory papillomatosis	10.4	EGFR TP53
31	bladder squamous cell carcinoma	10.4	CDKN2A TP53
32	keratinizing squamous cell carcinoma	10.4	CDKN2A TP53
33	benign breast adenomyoepithelioma	10.4	EGFR KRT7
34	spitz nevus	10.4	CDKN2A TP53
35	inverted transitional papilloma	10.4	CDKN2A KRT7
36	breast squamous cell carcinoma	10.4	EGFR TP53
37	oncocytic breast carcinoma	10.4	EGFR KRT7
38	scrotal carcinoma	10.4	CDKN2A TP53
39	thyroid lymphoma	10.4	CDKN2A TP53
40	bartholin's gland disease	10.4	CDKN2A TP53
41	malignant spiradenoma	10.4	KRT7 TP53
42	anal squamous cell carcinoma	10.4	CDKN2A TP53
43	spiradenoma	10.4	KRT7 TP53
44	microglandular adenosis	10.4	EGFR TP53
45	megaesophagus	10.4	CDKN2A TP53
46	gastric adenosquamous carcinoma	10.4	CDKN2A TP53
47	adenoid basal cell carcinoma	10.4	CDKN2A KRT7
48	bile duct adenoma	10.4	CDKN2A KRT7
49	endocervical carcinoma	10.3	CDKN2A KRT7
50	cervix uteri carcinoma in situ	10.3	CDKN2A TP53

Comorbidity relations with Vulva Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis	Clitoris Cancer
Hypertension, Essential	Localized Scleroderma
Vaginal Cancer	Vulvar Dystrophy

Graphical network of the top 20 diseases related to Vulva Cancer:

Sources

Symptoms & Phenotypes for Vulva Cancer

UMLS symptoms related to Vulva Cancer:

pelvic pain, pruritus vulvae

MGI Mouse Phenotypes related to Vulva Cancer:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	pigmentation	MP:0001186	9.26	CDKN2A EGFR LMO7 TP53
2	respiratory system	MP:0005388	9.1	CDKN2A EGFR LMO7 SCN10A SH3GL2 TP53

Sources

Drugs & Therapeutics for Vulva Cancer

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁹	Company	Approval Date
1	Gardasil ¹⁹ ⁵⁰	quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine	Merck	June 2006
FDA Label: Gardasil Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus Indications and Usage: ¹⁹ GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7) DrugBank Targets: - Mechanism of Action: ¹⁹ Target: humoral immune response Action: inducer FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Vulva Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Octreotide

Approved, Investigational

Phase 3

83150-76-9

6400441 383414

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Dehydroepiandrosterone

Approved, Investigational, Nutraceutical

Phase 3

53-43-0

9860744

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Liver Extracts

Phase 3,Phase 2,Phase 1

Cola

Phase 3,Phase 2,Phase 1

Fibrin Tissue Adhesive

Phase 3

Coagulants

Phase 3

Hemostatics

Phase 3

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Vaccines

Phase 3,Phase 2,Phase 1,Not Applicable

Gastrointestinal Agents

Phase 3,Phase 1

Antineoplastic Agents, Hormonal

Phase 3

Narcotics

Phase 3

Adjuvants, Anesthesia

Phase 3

Analgesics

Phase 3,Phase 2,Phase 1

Anesthetics, Intravenous

Phase 3

Anesthetics, General

Phase 3

Anesthetics

Phase 3

Analgesics, Opioid

Phase 3

Central Nervous System Depressants

Phase 3

Peripheral Nervous System Agents

Phase 3,Phase 2,Phase 1

Adjuvants, Immunologic

Phase 3,Phase 2,Phase 1,Not Applicable

DHEA (Dehydroepiandrosterone)

Phase 3

Indinavir

Approved

Phase 2

150378-17-9

5362440

Ritonavir

Approved, Investigational

Phase 2

155213-67-5

392622

Parathyroid hormone

Approved, Investigational

Phase 2,Phase 1

9002-64-6

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Tacrolimus

Approved, Investigational

Phase 2

104987-11-3

6473866 445643 439492

Pimecrolimus

Approved, Investigational

Phase 2

137071-32-0

17753757 6447131

Clobetasol

Approved, Experimental, Investigational

Phase 2

25122-46-7, 25122-41-2

5311051 32798

Fondaparinux

Approved, Investigational

Phase 2

104993-28-4

Gemcitabine

Approved

Phase 2,Phase 1

95058-81-4

60750

Imiquimod

Approved, Investigational

Phase 2,Not Applicable

99011-02-6

57469

Ipilimumab

Approved

Phase 2,Phase 1

477202-00-9

nivolumab

Approved

Phase 2,Phase 1

946414-94-4

Daratumumab

Approved

Phase 1, Phase 2

945721-28-8

Fludarabine

Approved

Phase 1, Phase 2,Phase 2

75607-67-9, 21679-14-1

30751

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

Aldesleukin

Approved

Phase 1, Phase 2

110942-02-4, 85898-30-2

Durvalumab

Approved, Investigational

Phase 2,Phase 1

1428935-60-7

Bupropion

Approved

Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 2

62-31-7, 51-61-6

681

Pembrolizumab

Approved

Phase 2

1374853-91-4

Irinotecan

Approved, Investigational

Phase 2

100286-90-6, 97682-44-5

60838

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Serine

Approved, Nutraceutical

Phase 2

56-45-1

5951

Cytochrome P-450 Enzyme Inhibitors

Phase 2

Interventional clinical trials:

(show top 50) (show all 135)

#	Name	Status	NCT ID	Phase	Drugs
1	Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva	Completed	NCT00003325	Phase 3
2	Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes	Completed	NCT00898352	Phase 3
3	Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva	Completed	NCT00028951	Phase 3	fibrin sealant
4	Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage	Completed	NCT00224744	Phase 3
5	Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)	Completed	NCT00092521	Phase 3
6	Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence	Completed	NCT01148290	Phase 3
7	A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)	Completed	NCT01047345	Phase 3
8	Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)	Completed	NCT00543543	Phase 3
9	Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)	Completed	NCT03158220	Phase 3
10	A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)	Completed	NCT00090220	Phase 3
11	Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam	Completed	NCT03546842	Phase 3
12	Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis	Completed	NCT00033605	Phase 3	octreotide acetate
13	GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)	Completed	NCT01245764	Phase 3
14	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
15	A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)	Completed	NCT00092547	Phase 3
16	Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms	Completed	NCT01376349	Phase 3	prasterone
17	Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery	Recruiting	NCT02997553	Phase 3	Indocyanine green;Technetium99
18	A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)	Active, not recruiting	NCT00943722	Phase 3
19	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva	Terminated	NCT00006096	Phase 3	cisplatin
20	Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer	Terminated	NCT00577317	Phase 3
21	Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy	Unknown status	NCT01406769	Phase 2
22	Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer	Unknown status	NCT00905658	Phase 2
23	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases	Unknown status	NCT00637637	Phase 2	indinavir sulfate;ritonavir
24	Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva	Completed	NCT00014599	Phase 2	paclitaxel
25	Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva	Completed	NCT00068406	Phase 2	Cisplatin
26	The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence	Completed	NCT01986725	Phase 2
27	Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar	Completed	NCT00476476	Phase 2	Erlotinib
28	Effectiveness of an Individualized Symptom Education Program (ISEP)	Completed	NCT00275353	Phase 2
29	Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers	Completed	NCT00545792	Phase 2	Avastin
30	Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus	Completed	NCT00393263	Phase 2	pimecrolimus and clobetasol;clobetasol 0.05% cream
31	A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)	Completed	NCT00551187	Phase 2
32	Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)	Completed	NCT00520598	Phase 2	Comparator: V505 formulation 2;Comparator: V505 formulation 2
33	Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer	Completed	NCT00381888	Phase 2	fondaparinux sodium
34	Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies	Completed	NCT01079832	Phase 2
35	Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer	Completed	NCT01764802	Phase 2
36	Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva	Recruiting	NCT01595061	Phase 2	Cisplatin;Gemcitabine Hydrochloride
37	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Recruiting	NCT02834013	Phase 2
38	Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers	Recruiting	NCT03403465	Phase 2
39	An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors	Recruiting	NCT02488759	Phase 1, Phase 2	Nivolumab;Ipilimumab;Relatlimab;Daratumumab
40	Image-Guided Gynecologic Brachytherapy	Recruiting	NCT02993900	Phase 2
41	E7 TCR T Cells for Human Papillomavirus-Associated Cancers	Recruiting	NCT02858310	Phase 1, Phase 2	Aldesleukin;Fludarabine;Cyclophosphamide
42	DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated Cancers	Recruiting	NCT03439085	Phase 2
43	Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer	Recruiting	NCT03180294	Phase 2	Bupropion Hydrochloride
44	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)	Recruiting	NCT02628067	Phase 2
45	Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)	Recruiting	NCT03180684	Phase 2	Imiquimod 5% cream
46	Image-Guided Gynecologic Brachytherapy	Active, not recruiting	NCT01399658	Phase 2
47	Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva	Terminated	NCT00003525	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)
48	Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer	Terminated	NCT00106262	Phase 2	Velcade (bortezomib);Irinotecan
49	Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma	Withdrawn	NCT03220009	Phase 2
50	Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions	Unknown status	NCT00066404	Phase 1

Search NIH Clinical Center for Vulva Cancer

Cochrane evidence based reviews: vulvar neoplasms

Sources

Genetic Tests for Vulva Cancer

Sources

Anatomical Context for Vulva Cancer

MalaCards organs/tissues related to Vulva Cancer:

⁴²

Lymph Node, Testes, Skin, Cervix, Brain, Tongue, T Cells

Sources

Publications for Vulva Cancer

Articles related to Vulva Cancer:

(show all 38)

#	Title	Authors	Year
1	Impact of re-excision of residual adjacent vulvar intraepithelial neoplasia (VIN III) and histological tumour-free margin (hTFM) on survival in primary squamous cell carcinoma of vulva. ( 30187190 )	Gasimli K...El-Balat A	2018
2	Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review. ( 29420364 )	Froeding LP...European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group	2018
3	Adenoid Cystic Carcinoma of Vulva-11 Years' Single-Institution Experience. ( 28546667 )	Johnson LR...Ahamed IM	2017
4	Locally advanced vulva cancer: A single centre review of anovulvectomy and a systematic review of surgical, chemotherapy and radiotherapy alternatives. Is an international collaborative RCT destined for the "too difficult to do" box? ( 28034465 )	O'Donnell RL...Naik R	2017
5	Vulva cancer in Ghana - Review of a hospital based data. ( 28409179 )	Dadzie MA...Vanderpuye V	2017
6	Surgical management for squamous cell carcinoma of vulva. ( 27642483 )	Amavi AK...Jalil A	2016
7	Could sentinel node mapping of the groin cause extranodal metastasis in vulva cancer? ( 25412581 )	Abdul Wahab NA...Gleeson N	2015
8	An unusual case of mammary gland-like carcinoma of vulva: case report and review of literature. ( 26189264 )	Baykal C...Ozyar E	2015
9	Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana. ( 25225572 )	Simbiri KO...Robertson ES	2014
10	Preliminary study on human papillomavirus frequency and specific type-distribution in vulva cancer from Thai women. ( 23725140 )	Ngamkham J...Swangvaree SS	2013
11	Tumor-to-tumor metastasis with endometrial carcinoma metastatic to squamous cell carcinoma of vulva: the first reported case. ( 24283863 )	Wimmer JL...Ro JY	2013
12	Verrucous squamous cell carcinoma of vulva simulating multiple epidermal inclusion cysts. ( 23919011 )	Lorente AI...Conejo-Mir J	2013
13	The comparative study of former and latest FIGO staging of vulva cancer. ( 22487921 )	Sun X...Cheng H	2012
14	Small cell carcinoma of vulva: curative multimodal treatment in face of resistance to initial standard chemotherapy. ( 20803181 )	Eckert F...M?ller AC	2010
15	Treatment outcome of patients with carcinoma of vulva: experience from a tertiary cancer center of India. ( 21358089 )	Sharma DN...Sahai P	2010
16	Assessment of promising protein markers for vulva cancer. ( 19509584 )	Fons G...van der Velden J	2009
17	Cyberknife radiosurgery for squamous cell carcinoma of vulva after prior pelvic radiation therapy. ( 18783287 )	Kunos C...Einstein D	2008
18	Verrucous carcinoma of vulva. ( 17917632 )	Kabir N...Muhsin AU	2007
19	An alternative approach to ganglion impar neurolysis under computed tomography guidance for recurrent vulva cancer. ( 17006101 )	Ho KY...Huh BK	2006
20	Images in pathology. Invasive squamous cell carcinoma of vulva that wanted to be a puppy. ( 17041202 )	Mittal K...Da Costa D	2006
21	Clinico-pathological profile of vulva cancer in southern Thailand: analysis of 66 cases. ( 16149671 )	Hanprasertpong J...Geater A	2005
22	Invasive squamous cell carcinoma of vulva: prognostic significance of clinicopathologic parameters. ( 15861524 )	Nola M...Jukic S	2005
23	Correspondence re: Weiderpass et al., Alcoholism and risk of cancer of cervix uteri, vagina, and vulva. Cancer Epidemiol. Biomark. Prev., 10: 899-901, 2001. ( 11895888 )	Chiaffarino F...La Vecchia C	2002
24	Response to "Inguinal node status by ultrasound in vulva cancer" (Abang Mohammed et al. Gynecol Oncol 2000;77:93-6). ( 11277664 )	Moskovic E	2001
25	Treatment of verrucous carcinoma of vulva with acitretin. ( 10848746 )	Mehta RK...Sterling JC	2000
26	Inguinal node status by ultrasound in vulva cancer. ( 10739696 )	Abang Mohammed DK...Monaghan JM	2000
27	Cervical and vulva cancer: changes in FIGO definitions of staging. ( 8624311 )	Shepherd JH	1996
28	T2/3 vulva cancer: a case-control study of triple incision versus en bloc radical vulvectomy and inguinal lymphadenectomy. ( 7774837 )	Siller BS...Austin JM	1995
29	Concurrent squamous cell carcinoma of vulva and penis in a married couple. ( 3373472 )	Nally C...White H	1988
30	Therapy of advanced epidermoid carcinoma of vulva. Report of 13 patients, with review of recent literature. ( 1165879 )	Krupp PJ...Batson HW	1975
31	Cutaneous basal cell carcinoma of vulva. ( 1192371 )	Cruz-Jimenez PR...Abell MR	1975
32	Carcinoma of vulva in Singapore: a review of 12 cases. ( 5084234 )	Tan PM...Ratnam SS	1972
33	Effects of long-term administration of busulfan. Report of a patient with generalized nuclear abnormalities, carcinoma of vulva, and pulmonary fibrosis. ( 5255526 )	Feingold ML...Koss LG	1969
34	SURGICAL TREATMENT OF CARCINOMA OF VULVA. ( 14214238 )	CHENG YC...HU CY	1964
35	Intraepithelial and infiltrative carcinoma of vulva: Bowen's type. ( 13680991 )	ABELL MR...GOSLING JR	1961
36	Infiltrative squamous cell (epidermoid) carcinoma of vulva. ( 13707356 )	GOSLING JR...LOUGHRIN TD	1961
37	Carcinoma of vulva following granuloma inguinale. ( 12996727 )	MACKAY CR...BUNCH WL	1952
38	A case of carcinoma of vulva secondary to a primary growth in the breast. ( 20996160 )	JEFFCOATE TN	1946

Sources

Genes for Vulva Cancer

Genes related to Vulva Cancer (0 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	EGFR	Epidermal Growth Factor Receptor	Protein Coding	24.6	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶	8912181 18618485 11262056
2	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	22.87	DISEASES inferred ¹⁵ ¹⁵
3	TP53	Tumor Protein P53	Protein Coding	22.12	DISEASES inferred ¹⁵ ¹⁵
4	KRT13	Keratin 13	Protein Coding	20.28	DISEASES inferred ¹⁵ ¹⁵
5	KRT7	Keratin 7	Protein Coding	20.03	DISEASES inferred ¹⁵ ¹⁵
6	PLXDC2	Plexin Domain Containing 2	Protein Coding	19.28	DISEASES inferred ¹⁵ ¹⁵
7	UPK3A	Uroplakin 3A	Protein Coding	18.67	DISEASES inferred ¹⁵ ¹⁵
8	SCN10A	Sodium Voltage-Gated Channel Alpha Subunit 10	Protein Coding	18.41	DISEASES inferred ¹⁵ ¹⁵
9	SERPINB3	Serpin Family B Member 3	Protein Coding	18.39	DISEASES inferred ¹⁵ ¹⁵
10	LMO7	LIM Domain 7	Protein Coding	18.35	DISEASES inferred ¹⁵ ¹⁵
11	SH3GL2	SH3 Domain Containing GRB2 Like 2, Endophilin A1	Protein Coding	18.34	DISEASES inferred ¹⁵ ¹⁵
12	LINC01191	Long Intergenic Non-Protein Coding RNA 1191	RNA Gene	17.08	DISEASES inferred ¹⁵ ¹⁵

Sources

Variations for Vulva Cancer

Cosmic variations for Vulva Cancer:

⁹

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location
1	COSM12296	TP53	skin,lip,carcinoma,NS	c.292C>T	p.P98S	17:7676077-7676077
2	COSM10662	TP53	skin,lip,carcinoma,NS	c.743G>A	p.R248Q	17:7674220-7674220
3	COSM26363	PTCH1	skin,lip,carcinoma,NS	c.2446C>T	p.Q816*	9:95467230-95467230
4	COSM17598	PTCH1	skin,lip,carcinoma,NS	c.550C>T	p.Q184*	9:95485719-95485719
5	COSM498	HRAS	skin,genital,carcinoma,NS	c.182A>T	p.Q61L	11:533874-533874

Sources

Expression for Vulva Cancer

Search GEO for disease gene expression data for Vulva Cancer.

Sources

Pathways for Vulva Cancer

Pathways related to Vulva Cancer according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	L1CAM interactions ⁶⁷ Show member pathways CHL1 interactions ⁶⁷ Neurofascin interactions ⁶⁷ NrCAM interactions ⁶⁷	11.53	EGFR SCN10A SH3GL2
2	Glioblastoma Multiforme ⁶⁵	11.38	CDKN2A EGFR TP53
3	Oncogene Induced Senescence ⁶⁷	10.91	CDKN2A TP53
4	Photodynamic therapy-induced AP-1 survival signaling. ¹	10.84	CDKN2A EGFR TP53
5	Bladder cancer ¹ ³⁸	10.79	CDKN2A EGFR TP53 UPK3A
6	Inhibition of Ribosome Biogenesis by p14(ARF) ⁶⁵	10.71	CDKN2A TP53
7	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁷	10.66	CDKN2A TP53

Sources

GO Terms for Vulva Cancer

Biological processes related to Vulva Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of epidermal growth factor receptor signaling pathway	GO:0042059	9.16	EGFR SH3GL2
2	replicative senescence	GO:0090399	8.96	CDKN2A TP53
3	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	8.62	EGFR TP53

Molecular functions related to Vulva Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:0019901	8.92	CDKN2A EGFR SH3GL2 TP53

Sources

Sources for Vulva Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia